CA1073359A - Medicinal composition containing adrenal cortical hormone and thyroid stimulating hormone releasing hormone - Google Patents

Abstract

ABSTRACT OF THE DISCLOSURE
A medicinal composition comprising both adrenal cortical hormone and thyroid stimulating hormone releasing hormone has, as compared to adrenal cortical hormone alone, an enhanced therapeutic effect and reduced side effects.

Description

10~33S~

The present i~vention relates to a medicinal composition co~prising both adrenal cotrical hormone (hereinafter referred to as ACH) and thyroid stimulating hormone releasing hormone (hereinafter referred to as TSH-releasing hormone).
Heretofore, ACH has been administered to mammals for various pur-poses, e.g. to make use of the antiexudative, antipruritic, antiallergic, antiinflammatory, carbohydratemetabolism promoting, immunosuppressive and other acti~ities of such hormones. However, a large variety of diseases are too intractable ~o oe completely cured by ACH. Among such diseases are diarrhea and pneumonia in young animals of the weaning age, the onsets of which are said to be occasioned b~ various stresses and improper breeding _ 1 - ~

~: , .. .. .. .

3S~
, ~

conditions, chronic diarrhea in adult animc~ls~ pruritic chronic skin dis-eases such as eczen~, external and internal otitis which are chronic ex-udative diseases, and pustular interdigital pyodermatitis.
Moreover, if used in an improper m~nner or :in an unsuitable dose, and, for that matter, even when used at a norm~l dose level, ACH causes such troubles as a decline in milk production (Journal of the American Veterinary Medical Association, Vol. 157, No. 7, pp. 941-946; Journal of Dairy Science, Vol. 56, No. 7, pp. 896-902). This has posed problems in the application of such a hormone to nan~als. For example, significant declines in milk prod-uction are observed even when medicinally acceptable doses of ACH are applied to do~.estic animals (e.g. dairy cows and goats) with nastitis, ketosis, `~
arthritis, dermatitis, endometritis, vaginitis, allergic diseases or inabil-ity to stand before and after parturition and it is for this reason that the use of ACH is substantially restrlcted. It has, therefore, been a desider-atum to have a procedure developed to arrest the decline of milk production which would otherwise be caused by the application of ACH for the cure of diseases.
m e invention is based on the surprising discovery that, by dosing a manm21 with TSH-releasing hormone in conjunction with ACH, there can be obta-ined an outstanding therapeutic effect which cannot be obtained by the adninistration of ACH alone~ and the side effects of ACH can be suppressed.
The above finding was followed by further research which has culminated in the completion of this invention.
Thus, according to the invention, there is provided a medicinal composition comprising both ACH and TSH-releasing hormone in a ratio of about 1 (dexamethasone equivalent): 0.05 to 5.
The ACH employable according to this invention may be natural or synthetic, thus being exemplified by 9~-fluorocortisone, 9~-fluorocortisol, prednisone, prednisolone, triamcinolone (9~-fluoro-16~-hydroxyprednisolone), .~
-i 0~ 3 359 midrol (6~-methylprednisolone), de~amethasone (9~-fluoro-16~-methylpredniso-lone), betamethasone (9~-fluoro-16~-methylprednisolone), paramethasone (6~-fluoro-16~-methylprednisolone), flumethasone (6~, 9a~-difluoro-16~-methylpred-nisolone) and so forth. Among these, de~amethasone, betamethasone and flumethasone are conveniently employed. The ACH may be employed in the ~orm of physiologically acceptable esters, such as phosphates, acetates, niconi-nates, etc. or physiologically acceptable salts such as alkali metal salts, e.g. sodium, potassium and lithium salts, and alkaline earth metal salts, e.g. calcium salts.
The TSH-releasing hormone is commonly exemplified by L-pyroglutam-yl-L-histidyl-L-prolinamide (thyrotrophin releasing hormone; TRH) and com-pounds having TRH-like activity, such as L-2-oxooxazolidine-4-carbonyl-L-histidyl-L-prolinamide, L-trans-5-methyl-2-oxooxa2O1idine-4-carbonyl-L-his-tidyl-L-prolinamide, L-2-oxothiazolidine-4-carbonyl-L-histidyl-L-prolinamide (German Patent Application P 2408324.? laid open to public inspection on August 29, 1974 as OIS 2408324) and so forth. These hormones may also be employed in the form of physiologically acceptable salts such as the acid addition salts of inorganic acids (e.g. hydrochloric acid, etc~) and of organic acids (acetic acid, tartaric acid, etc.).
The medicinal composition of the in~ention, containing both ~CH
and TSH-releasing hormone, may be prepared in optional dosage ~orms such as injections (intramuscular, subcutaneous, intra~enous, etc.), oral prepara-tions (powders, tablets, capsules, pills, etc.)~ topical preparations (oint-ments, liquids, sprays, aerosols, etc.), infusions and implants (intrauterine, intramamm~ry,etc.) and so forth by per se known procedure. Particularly ad-vantageous are injections and topical preparations, the fonmer being frequent- ;
ly preferred.
The relative amounts of ACH and TSH-releasing honmones may be de-termined according to the particular dosage form, the disease to be treated and other factors.

, ~ ,.,. , , , ~:

~3359 Generally speaking, the ratio is about 1 (dexame-thasone equivalent): 0.05 to 5, advantageously 0.05 to 2, and especially 0.1 to 1, The preferred ratio in each dos~ge form is; in the case of injections, about 1 (dexamethasone e~uivalen-t): 0.~5 to 1, advantageously 0.1 to 1; in the case of oral preparations, about 1 (dexamethasone equiva-len-t): 1 to 5, advantageously 1 to 2; and in the case o~
topical preparations, in~usions and implants,about 1 (dexamethasone equivalent): 0.5 to 5, advantageously 0.5 to 2. The 'dexamethasone equi~alen-t' is an index number representing the relative clinical effect of any ACH with the effect o~ dexamethasone being taken as unity. The equivalent values for some typical ACH are given below.

ACH Clinical ef~ect 1 Dexamethasone 30.0 Hydrocortisone 1.0 30 Prednisolone 4.0 7.5 Prednisone 4.0 7.5 Methylprednisolone 5.0 6 Triamcinolone 5,0 6 Paramethasone 10.0 Betamethasone . ~0 Flumethasone 150 0.2 ~1: "Adverse Reactions to Drugsl' p.~l7(1975), published by Takeda Chemical Industries, ~td , Japan.
It will thus be clear that, according to this inven-tion, betamethasone, as used in lieu of dexamethasone, may be used in the same proportion as dexamethasone but, where ~, 4 -, , ~ . ,, . :

.:

~ 3~

use is made, for instance, of triamicinolone, the clinical efficacy of which is one-sixth o~ th~t of dexamethasone, the preferred compounding ratios are; in the case of in~jec-tions, about 6 (triamcinolone). about 0 05 to 1 (thyro-trophin releasing hormone); in the case o~ oral prepara-tions, about 6: 1 to 5; and in the case of topical prepara-tions, infusions and implants, about 6: 005 to 5.
In the manufacture of the medicinal composition according to this invention, use may be made of a suitable carrier or vehicle, if necessary, As examples of such carrier or vehicle, various materials that will not inter-fere with the activities of the medicaments may be men-tioned Thus, excipients, binders~ lubricants, colorants, flavorants, odoriferants, suspending agents, solubilizers and so forth may be incorporated, In addition to such vehicles, the medicinal composition of this invention may further contain various kinds of medicines for supple-menting the effect o~ the medicinal composition of the present invention or for expecting concomitantly other medicinal effect. As such medicines, there may, for example, be vitamins such as pantothenic acid, nicotinic acid, vitamin Bl, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, biotin, folic acid, vitamin ~, vitamin E, vitamin P, inositol, orotic acid, lipoic acid, etc.; compounds having vitamin-like activities (e.g. the corresponding derivatives, salts, etc.); an-timicrobial agents such as tetracycline, chlortetracycline, oxytetra-cycline, chloramphenicol, neomycin, dextromycin, kanamycin, _ 5 _ ".i ... . . .. . . . . .. . . .

~ .. , . . -~ . :

` i , . . . , ' , , . !
, 1~3359 trichomycin~ mikamycin, penicillin, ampicillin, sulfoxacillin, cephalosporin, sulfaisomidine, sulfaisooxazole, sulfadi-methoxine, sulfachloropyridazine, sulfamethazine, sulfa- -~
isazole, sulfamethoxypyridazine, etc., including their salts and other derivativesq streptomycins such as dihydro-streptomycin, streptothricin, streptomycin, etc. 9 macrolide antibiotics such as oleandomycin, leucomycin, tylosin, erythromycin, spiramycin, lincomycin, pikromycin and so forth When used against the various diseases in mammals for which ACH have heretofore been indicated, the medicinal composition of this invention accomplishes satisfactory therapeutic effects which cannot be obtained by the applica-tion of ACH alone Particularly, in such cases as -~xudative diseases (e.g. external otitis, internal otitis, interdigital pyodermatitis, etc.), pruritic diseases (e.g eczema, chronic eczema, etc.), allergic diseases (e.g. diarrhea in young animals in or near the weaning stage, chronic diarrhea in adult animals~ etc.), inflammatory diseases (e.~, pneu monia, bronchitis, etc.) and so forth, the composition accomplishes outstanding therapeutic effects of the order which cannot be obtained by conventional chemotherapy.
As aforementioned, the medicinal composition of this inven-tion is ch~racterized by its eminent therapeutic effects~
In addition, the present drug offers another advantage, that the presence of TSH-releasing hormone therein suppresses the physiological functional disorders that would otherwise be caused by the sole use of ACHo ~or example, ~hen a _ 6 _ ., . .. , . . : : .
.. , .. ; .

~. .. , : . . ...

~0'~335~

pharmaceutically effective dose of ACH is given -to animals (dairy cows, goats, etc.), a marked decline in milk produc-tion takes place, thus imposing a substan-tial limita-tion on the application of ACH. ~Iowever, the medicinal composi-tion of this invention does not cause such declines in mil~ production by virtue of the ~S~-releasing hor~one it contains.
The dosage of the medicinal composition of this in~ention is determined according to the subject m~m~al, the purpose of administration, the route of administration and other factors ~ormally, the composition is preferably administered at such a dose that the dosage level of the ACH contained in the composition will be the same as its dosage level ordinarily used when said hormone is used alone. It is also generally preferable to see to it that the titer of QCH will be 0 1 to 200 mg per doseO More particularly, for large animals such as cattle and horses, the preferred dose is 50 to 200 mg of prednisolone, 10 to 30 mg of dexame-thasone, ~ to 5 mg of flumethasone, 6 to 30 mg of triamcinolone or 10 to ~0 mg of betamethasone For intermediate animals such as pigs and sheep, the preferred dose is 10 to 50 mg of prednisolone, 0 5 to 10 mg of dexamethasone, 0 2 to 1 mg of flumethasone, or 2 to 10 mg of triamcinolone or betamethasone. ~or small animals such as dogs and cats, it is desirable to give 1 to 20 mg of prednisolone, 0.2 to 2 mg of dexamethasone, 0.2 to 0~5 mg of flumethasone, 1 to 3 mg of triamcinolone or 0.5 to ~ mg of betamethasone, to name but a few examples Generally, ~335~

the medicinal composition of this invention is applied once daily, normally for one to several days, If necessary, it may be given over an extended period of time a-t a frequency of once to twice weekly~
'~he following examples are intended to describe -this invention in further detail and should by no means be construed as limiting the scope o~ the invention.

Example Some examples of the medicinal composition according to this invention are prepared as follows:
A. In~jection (1) sodium dexamethasone phosphate 20 mg~

(2) '~RH 2 mg.

(3) phenol 100 mg.

(4) sodium metabisulfite 16 mg.

(5) ~aCl 180 mg.

All ingredients are dissol~ed in distilled water to make 20.0 ml of the solution (pH 6.5-7.5). '~he solution is suitably separated and filled into ampoulesO '~he atmos-phere in the ampoules are replaced with nitrogen gas. All the processes are conducted under sterile conditions.

, . . . . .
,: , : , : , . , , :.

~ 3359 B. H~dro~hilic ointment (1) dexamethasone 0.1 g.
(2) ~RH tartrate 0~1 g.
(3) propylene glycol 12,0 gO
(4) cetyl alcohol 2500 g.
(5) white petrolatum 25,0 gO

(6) pol~oxyethylene stearyl ether 500 gO

(7) methyl p-hydroxybenzoate0.025g.

(8) propyl p-hydroxybenzoate000l5g.

(9) distilled waterto make a total of 100 g.
A mixture of (4), (5) and (6) is heated to 75C to make Mixture I. On the other hand, ingredients of (1), (7) and (8) are dissolved in (3) under heating (Mixture II), and (2) is dissolved in (9) under heating (Mixture III).
Mixture III is added to Mixture II and the mixture is maintained at a temperature of 78C(Mixture IV). Mixture IV is added to Mixture I with stirring, and the resultant emulsion is cooled to solidify~

C. ablet (1) dexamethasone 0.5 mg.
(2) TRH 1,0 mg, (3) lactose 64.0 mg.
(4) corn starch 34.0 mg.
(5) magnesium stearateoO5 mg.
100.0 mg~
per tablet After mixing (1), (2~, (3) and 26 mg. of corn starch 1~335~

thoroughly, the mixture is granulated with paste prepared from 5 mg. of corn s-tarch The remaining 3 m~. of corn starch and (5) are added to the granules and the mixture is compressed into a table-t of 6~5 mm. in diameter.

Example 2 ~ reatment of eczema (in dogs) with an ointment containing dexamethasone and TRH (l:l).
In view of the fact that ACH ointment (0.1 /0) has been commonly indicated and used for eczema in dogs, the drug according to this invention was first given to 4 dogs with exudative eczema. ~irst, a hydrophilic ointment containing 0 1 % of dexamethasone phosphate was externally applied. As shown below, except that a passing mitigation of inflammation or itchness was noted in some of the eases, substantially no successful therapeutic result was obtained.
Rather, an adverse response, i.eO an increase in the amount of exudate, was in evidence and it was only in a single case that the ointment had a slightly beneficial effect Breed (site of lesion) Sex Age ap~licatior ment . . ~ , _ Bulldog (eczQma on neck and baek) Ilale One year 5 days (-) Tosainu (eczema on back and Male 2 years 5 days (-) belly) (eczema at tail root) ~emale 4 years 3 days (-) Spits Male 2 years 5 days (i) * ; a passin~ mitigation of inflammation or itchness ~hen, a hydrophilic ointment containing 0 1% each of , ~3359 dexame-thasone phosphate and ~RE tartrate was applied to 6 dogs. In all cases, the medication had marked effects as compared with using ACH alone, ~hus, the combined use of the two hormones resulted in the onset of response after 2 to 3 days in 5 dogs with exhudative eczema and one dog with exfoliative dermatitis, all the cases being successfully cured with the symptoms disappearing completely or nearly completely by the 3rd or 5th day.
Period of Breed of do~ Sex Age _ _ ap~lication Judgement Boxer Male 6 months 3 days (d+-+
of ear~ healed) Maltese and inside Male 1 year 4 days (dried and thigh) healed) Cocker spaniel (belly) lIale 6 months 3 days +++
~hibainu (neck and back) Female 3 years 5 days +-~
Bulldog (eye and forehead) ~emale 2 years 3 days ~ +
~Akitaken (roo-t of tail Male 1 year 3 days +-~
and belly) * Exfoliative dermatitis; Applied for 7 days to be on the safe side;Completely cured.
-~+ ; very effective ++-~; pronouncedly very effective Most of the above cases were treated for eczema, Significant reductions in cure time were obtained in all the cases to which the combined medication was applied and, .: ~.: . .. ;

even in the case with parasi.tic dermatitis, the redness disappeared with other clinical symptoms being improved, ~xam,~e Treatment of eczema, external otitis and intergital pyoderma (all in dogs) with dexamethasone-TRH (4:1 and 16:1) injections.
2,5 ml of a compound injection containing 2 mg of dexamethasone and 125 ~g o~ ~RE tartrate was intramuscularly' applied to each puppyO A single injection had excellent effects as shown in the ~ollowing table.

~:
~o~ + +
+ + +
a) +
, ~:1 Fl ~ u~ rl ~1 ~ O O :11 a) a) 1~ 0 ~ ~ 1 h a>
rl 1~ 13 F h ~d ~ ~ J h ~ r-J O rd Fl 3 u~ c) ~: ul r l ~H ~ ,5: t~ rd ~ ~-~ V 3 0 rd ~ ~ ~ ~rl ;rl ¦ ~rl u~ td O ~ N c; ~ ~r ~ ~rl ~ a~(~) a~ O cq ~I OJ
~1 ~ tl~ O E ;2 ~ a) ~rl ~rl El ~1 r ~ ,5~ rl ~,~ O El ~ ~ El Fl Fl t~ O r-l -~
h ~ ~ ~ ~D ~ ~ r~
~i ::5 N C) O h~rl Q) ~d u2 ~I Q) O U~ N ~ a~ h ~ D O
rl 5-1 0 4 h ~ l ~I d rl d O rd rl h O c~ r-l G) ~ ~1 ~1 ~ Fd a) a~ d¦ Lr~f~ L~-- Lr~
u~ h r~
Fl P~ rl Eo ~ ~ rl ~ E~ ~ g ~1 El N N h N
P~ c) o ~1 C.) ~J2 ~1 ~1 ~ a ~
h bD ~J u~ ` O 0~1 rl ,!Y~
O ~) u2 r~ ~Q Ul ,~ CQ
h~C~ CO t[S
a) a)o o a~
~1 ~ h o h h a) ~
~d ~d rl ~D ~LI ~ ~1 ~D ~Ca) (I~ ,D
mh ~ u- u2 O ~1 0~1 ~;

, . .
~ ', `` ':` ',: ` ' ' ` `, . ' ' ~0~3359 ~ hen, an injection was prepared using 1 mg of dexa-me-thasone and 0.1 mg of ~RH per milliliter and instramus-cularly given to 3 dogs with eczema and 2 dogs with external otitisO The itchness disappeared in 2 to 3 days and the rank odor, pus formation and eczema were improved in 5 days, There also was a case in which the red spots disappeared on the next da~ following the injection. ~he injection was given three times to each of 2 dogs with chronic eczema.
One was injected three times a day and other was injected twice in a day and once again after a week. Both case showed marked ef~ects and the latter was completely cured.

4, Doberman 2 ~ 31 Eczema 30 ~he residue of (~) (ml) shampoo at the root of the tail caused the eczema. (~leansed with Serene~ , ~he itchness disappeared on the 3rd day, 5, Maltese . 3.5 ~ 3.8 ~xternal 20 ~he expulsion (+-~) otitis of pus was smooth and the odor was eliminated in 3-4 days, ~he dog became indif~erent after a weekO

6, Hybrid 4 o I7 Chronic 20 Bathing with (+) eczema Muto Ha ~ every day. ~hree inJ ections eliminated the itchness, Complete cure after 40 daysD

:

33S~

7. Colie 6 ~ 35 Eczema 40 The lesion (+~) cleansed. The itchness was eliminated on the 2nd day.
Th0 eczema also disappeared after 3 days.

8. Pomeranian 2 ~ 1.5 Eczema 10 The 5 to 7 red t~+) spots around the waist dis-appeared on the next day follow-ing the injec-tion.

9. Maltese 2 ~ 2.6 External 20 The ran;k odor, (~) otitis pus and itchness disappeared around the 5th day. Then, complete cure came after a single cleansing.

10. Hybrid 6 ~ 14 Chronic 20 Dosed for 2 (++) eczema consecutive days, and again after a week.
Complete cure after 2 weeks.

ample 4 Treatment of eczema (in dogs) with a betamethasone-TRH 0 (10:1) compound i~jection.
2.64 mg/ml of betamethasone, a synthetic ACM which is as potent as dexamethasone, was mixed with 250 ~g/ml of TRH to prepare an injection, and two dogs with eczema were intramuscu-larl~ treated once. A single injection had a marked effect, observed after 3 to 7 days, resulting in complete or nearly com-plete cure.

~-: . ' :,.

~ 0~3 35~

1. Hybrid 12 ~ 13 Ec~ema 20 ml Infiltrating ec~ema at the root of the tail;
cleans~d with Serene . Dried out in a week.

2. Hybrid 3 ~ 17 Eczema 23 ml Gorticoid (++) externally applied as adjunct.
Complete cure after 3 days.

Example S

Treat~ent of interdigital pyoderma (in dogs) with a dexamethasone-TRH (4:1) compound injection.
This is an intractable skin disease with deep pyo-derma which is caused by infection with a Staphylococus organ-ism. The symptoms include exudative and pustular lesions.
As in the case of eczema, the conventional remedy consists of injections of an antiinflammatory or/and anti-allergic agent at frequent intervals. As an adjunct, injec-tions of an antibiotic to which the causative organism is sen-sitive has also been indicated. Because of the great depth of20 the lesion, the disease has been found to be difficult to cure completely and, in not a few cases, the emergence of a resis~
tant strain of organism is responsible for the prolonged course of the disease. In the following case, by culture of the pus-like exudate collected from the lesion, the causa~ive agent was identified as a kanamycin-resistant strain of Staphylococus.
The course was chronic, accompanied by exudates and pain at ~ ', ,, ~ ,~ :

~73359 the site, and a surgical treatment was reasonabl-~ indicated.
However, daily injections of a mixture of 2 mg dexamethasone (2 ml) and 500 ~g ~F~I (2 ml) resulted in a marked mitiga-tion of the redness and swelling of the lesion after 3 days, and the symptoms were su~stantially absent, with lameness cured, on the 5th day.
A his-tological examination of the lesion (in the 4-th interdigital fold) demonstrated a complete heal. By the end of 3 months, there was a complete cure without a relapse. ~he age and breed of dog:
Bulldog, male, 18 months old. Pyoderma between the 3rd and 4th digits o~ -the right front paw and at the 2nd and 3rd digits of the left front paw.

~ reatment of chronic moist dermatitis (in dogs) with dexamethasone-~RH tartra-te (1:2) tablets Akitaken (dog): 2 years and 6 months old, male, ~5 kg Diagnosis: Chronic moist dermatitis ~ he onset had come at the buttocks and the root of the tail, and had been treated with ACH without success First, one tablet of 0.5 mg dexamethasone failed to elicit a response. ~herefore, on the next day one tablet con-taining 0 5 mg of dexamethasone and 1 mg of TRH tartrate was orally administered Because the medication caused the lesion to start drying, another tablet was gi~en on the 3rd day. As an adjunct to the medication, -the dog was placed on a controlled regimen. ~he resul-t was a complete cure~

~ 16 -; , , ` . : ., ~ , .
.,: . .. ..

! . ~0~3359 ~Z
Treatment of diarrhea (white diarrhea) in young pigs with a dexamethasone: TRH (10:1) compound injection, Eight young pigs with body weights :in the range of 2~5 to 4 kg, 15 days old (an injection of an antibiotic (1 ml of tylosin, I,Mo) on the day immediately preceding the weaning was given for the prophylaxis of respiratory diseases but there was diarrhea on the next day~ were intramuscularly dosed with a compound injection containing 1 mg of dexamethasone and 100 ~g of TRH per 1A2 ml, In all cases, the feces became normal, with no subsequent abnor-~alities, Example Q
Treatment of diarrhea in dogs and cats, young and adult, wlth dexamethasone-TRH (6-1:1) compound injections, Using mixtures of dexamethasone and TRH in the ratios of 6:1, 2 1 and 1:1, the following 9 dogs, young and adult, and one young and one adult cats were intramuscularly medicated once~ In all cases, a complete cure was o~tained, ., ~ , ..

~ Dexamethasone 1 mg/ml; TRH 0.5 mg/2 ml Breed A e Body Dose* Cure - ~ k~ ml:m:Lconfirmed M~ltese (6:1) (male dog) 8 months 3 0.3:0.2 10 days(+-~+) Persian 4 years 5 0.3:().2 10 days(-~++) (female cat) (4:1) Pomeranian 3 months 0.8 0,1:0,1 7 days(+++) (male dog) :Dachshund 6 mon-ths 9 0.3:0.3 14 days(~+) (male dog) Shibainu 3 months 2,5 0,1:0.1 14 days(+++) (male dog) Maltese 2 months 1.8 0.1:0.1 14 days(~++) (female dog) Shiamese 6 months 3 0.2:0,2 3 days(+++) (cat) (1:1) Kantonken 8 years 8 0~2:0,4 28 days(+++) (male dog) D~chshund 4 months 1.5 0,1:0,2 21 days(~++) (male dog) S~itz 7 years 9 0.2:0,~ 21 days(~++) hybrld, female dog) Example 9 ~ reatment (antitussive) of bronchitis (in dog) with a dexamethasone-TRH(10:1) compound injection.
Hybrid dog, 8 years, 15 kg, laryngobronchitis Appetite normal, body temp, 38,7C~ with severe coughing A compound injection of 2 mg dexamethasone (2 m~) and 0.2 mg ~RH(4 ml) caused the coughing to subside on the next day, Then, the dog was further medicated a-t the same dose. ~here was a complete cure on the 4th day~

. ~ ~ . . . .. .. .. . .. .

' ~ : ,;. ' " ,. . ~ ~ :
. . : ~ ~ . . , : .:
:: : : ., . :, - , .. .:, 0'73 ~ 5~

Examp~e 10 For each of Group A of animals comprising three healthy dairy cows ~average daily milk productions: 17.5 (Al), 15.8 (A2) and 1S.5 (A3), kg.) subcutaneously injected with 10 ml of an aque-ous solution of 10 ~g de~amethasone phosphate, Group B comprising three healthy dairy cows (average daily product:ions of milk: 15.5 (Bl), 20.5 (B2) and 13.9 (B3) kg.) injected subcutaneously with 18 ml of an aqueous solution containing 10 mg of dexamethasone phos-phate and 2 mg of T~H (tartrate) and Group C (control) comprising three healthy dairy cows (average daily productions of milk: 12.7 (~ ), 9.1 ~C23 and 11.5 (C3) kg.), the amount of ~ilk secreted during the 8 days following the injection were measured and the variation from the average amount of milk production was deter-mined and expressed in percentage. The values and percents are given in Tables 1, 2 and 3.
Table 1 Group A

Al A2 A3 Day of Milk Milk Milk measurement produc- % produc- % produc- %
tion tion tion (kg) (kg) (kg) ~ay of injec- 18.5 105.7 15.7 99.3 13.0 83.8 tion 1 day after 12.4 70.8 12.6 79.7 10.1 65.1 injection 2 days " 14.9 85.1 14.6 92.4 11.3 72.9 3 days " 15.5 88.5 15.0 94.9 12.6 81_2 4 days " 17.2 98.2 15.2 96.2 12.2 78.7 5 days " 16.8 96.0 14.8 93.6 14.6 94.1 6 days " 17.0 97.1 16.3 103.1 12.8 82.5 7 days tt 17.3 98.8 15.3 96.8 13.6 87.7 :: .: : .. : . :
. ::- . :

10~335 Tab Group B
_e Bl B2 B3 Milk Milk Milk Day of produc- % produc- % produc- /0 measurement tion tion tion (kg) (kg) (kg) tion 16.9 109.0 22.9 111,714.0 100~7 injection 14.9 96.1 18.7 91,213.4 96.4 2 days " 16,6 107,0 19,6 95,614.4 103.5 3 days " 15.6 100.6 19.9 97.014.0 100,7 4 days " 14.4 92.9 20.0 97.513.0 93,5 5 days " 15.7 101.2 19.9 97,013.2 94.9 6 days " 16.6 107.0 20.8 101.413~2 94.9 7 days " 15.6 100,6 19.4 94.613.4 96.4 able 3 Group C
Cl C2 c3 Milk Milk Milk Day of produc- % produc- /0 produc- %
measurement tion tion tion (kg) (kg) (kg) ~ . . ~
Starting day 11,7 92.1 9.5105,5 11,5 100.0 1 day after 13.0 102,3 9.8 108,811.1 96.5 2 days " 13.0 102.3 9.4104~4 11,9 103.4 3 days " 13,2 103.9 8.997.8 10.7 93.0 4 days " 12,8 100,7 9.8107,6 10.0 86,9 5 days " 13,9 100,9 9,3102.1 11~7 101.7 6 days " 12.0 94.4 10.0109.8 12,5 108.6 7 days " 13.1 103.1 8.391.2 12~2 106.0 20 ~

.. ~ , ..

. - . . ~ :- . .. .

. . .

~733~

It will be seen from ~ables 1, 2 and 3 that the declines in milk secretion due to dexamethasone can be definitely arrested by dosing the animals with TRHo The trend of milk production i~ Group B (dosed. according to this invention) was substantially the same as that observed for Group C (control), A solution of 10 mg of dexamethasone phospha-te in 10 ml of water and a solution of 20 mg of said agent in 20 ml of water were each used to dose animals subcutane-ously along with the simultaneous applica-tion of 1 mg and 2 mg, respectively, of ~RH (in each combination~ the weight ratio was 10.1). The amounts of milk produced during one week following the injections were measured and compared with the amounts of milk production during one week befo.re the injections and during the second week following the injections. The results are shown in Table 4.

~ab 4 Milk production(average + standard deviation) kg ~ .
1 week before 1 week after During 8-14 Dosage injection injection days after ~ ~ in~iection Dexamethasone 10 mg 13.09 ~ 0.75 13,20 _ 0.9 p osp a e ~11.84 + 0.81 TRH 1 mg (12.46 + 0.99) Dexamethasone20 mg8.43 + 1.82 9,36 _ , 7 p osp a e 8.24 + 0,65 TRH 2 mg(8034 + 1.31) *: The average milk productions for one week before the .. , . . ~
, ' '~ . . ! '.
.' "' ' ":'' , ', . ~
'' ' ,~'' ' ,' . .
~. . ,, ', . " '" '.,.

1~7335~

injection and during the 8th to 14th days after the injection.
~ he above experimental data show that, statistically, the milk production of the group dosed with both de-xametha-sone phosphate and ~RH at the same time is not si~nificantly different from the production of milk in the control group.

~ .
A Holstein cow with a body weight of 662 kg. was intramuscularly dosed with 10 ml of an aqusous solution of 10 mg betamethasone and 4 ml of an aqueous solution of 1 mg q'RH and the amounts of milk produced before and after the injec-tion were measured and compared. '~he results are set forth in ~able 5.

able _~
Milk Milk Day of produc- Day of produc-measurement tion, measurement tion, kg kg ~.. _, . . ~ .. .. .
injection 13.9 2 days after injection 12,6 3 days " 13.7 3 days after injection 14.6 2 days " 14,8 4 days after injection 13,6 1 day " 1402 5 days after injection 12.0 :injection 13.7 7 days after injection 13.2 YCtion 12.9 It will be apparent from ~able 5 that no decline in milk production occurred when both betamethasone and ~RH
were injected, 22 ~
.
. ,.. ., . , . " .... .
- ....
, :..... . . . . ...
. ,, : . . : . .
:, ,. : - . : ~ . .
.:: . : . .:, . . ,;
.. -. . :. :. , ~ : :~

~33~9 A Holstein cow weighing 654 kg was intramuscularly dosed with 10 ml of an aqueous solution of 10 mg flumetha-sone and 4 ml of an aqueous solution of 1 mg TRH, and the amounts of milk produced before and after the injection were measured and compared. ~he results are set forth in ~able 6.

Ta~le 6 Day of Milk Day of Milk measurement production, measurement production~
kg kg 4 days before 18.5 2 days after 14,8 i.njection injection 3 days " " 18.03 days " " 19,8 2 days " " 16.54 days " " 15.4 1 day " " 14,95 days ll ll 13.3 Day of injection 15.2 7 days " " 1405 Ytafter 140910 days " " 15,7 n~ec lon It will be apparent from Table 6 that the injection of both flumethasone and TRH prevents a decline in milk production.

Example 14 A dairy cow, 3 years old, with chronic mastitis in which the clots (flakes) (++) in milk had persisted even after the application of a synthetic penicillin over the preceding month was intramuscularly administered with a mixed solution of 10 mg of dexamethasone and 1 mg of TRH in dis-tilled water for injections at the frequency of once a day . . . .

~335~

for two consecutive days This treatment resul-ted to the disappearance of milk flakes and the cow could thereafter be managed as a healthy animal. Table 7 below shows the amounts of milk production before and after the injection.

~Z
Milk Milk Da~ of production, Day of production, measurement kg measurement kg .
4 days before 1 da~ after injection 80~ start of injec-tion 6~0 days " " 8 ,1 2 days " " 5 0 5 2 days " " 706 3 days " " 7.8 Starting day f 6 .L~ 4 days " " 7 7 It will be apparent from Table 7 that the application of TRH in conjunction with the application of dexamethasone cures chronic mastitis without a decline in milk production.

Example 1~
A dairy cow, 5 years old, with unilateral polycystic follicles was subjected to two follicle disintegrating -treatments but could not be cured, with andromaniac symptoms persisting. Therefore, the cow was intramuscularly dosed with a mixed solution of 10 mg dexamethasone and 1 mg of ~R~ in distilled water for injections. The luteinization of follicles began to be in evidence on the sixth day after the injection and an unmistakable sign of estrus was noted on the 22nd day. Artificial insemination, therefore, was carried out. The amounts of milk produced before and - .. . : : .: . . .
.: :, . , , ~ , .. . : . .
,. , . . :: :: ...
~ , ,:, .
., : . .:
.. , .,. :.: , lQ'733S9 after the injection are shown in ~able 8.

~eble a Milk Milk Day of production, Day of production~
measurement kg measurement kg , . . _ ~ _ . _. .~
4 day before 17 0 1 da~ after 16 7 injection injection o days " " 16.8 2 days " " 16.5 2 days " " 17.5 3 days " " 16.8 1 day " " 16.0 4 days " " 16,0 Day of injection 16,5 5 days " " 17.2 It is apparent from ~able 8 that the application of ~RH along with dexamethasone leads to a cure of ovarian follicle cyst without affecting the secretion of milk, ~' Ketone bodies were found in the milk of a dairy cow towards a peak of milk production. ~he cow with latent ketosis, therefore, was intramuscularly dosed wi-th a mixed solution of 10 mg of dexamethasone and 1 mg of ~RH in 10 ml of distilled water for injections once daily for two con-secutive days. ~he ketone bodies diappeared and the cow went in~o a peak production phase. ~he amounts of milk produced before and after the treatment are shown in Table 9.

.. .. . , , . " . ~
,: : . :~ . ;.
, . , ., ~ ,., . ~ , :
.. . :. . . . .

~able 9 Milk Milk Day of prodwction, Day of production, measurement kg measuremen-t kg 3 days before 27 0 1 day after first first injection injection 21,0 2 days " " 25,0 2 days " " 20,6 1 day " " 21.3 3 days " " 22.5 Day of first injection 20.0 4 days " " 23.4 It will be apparent from ~able 9 that the application of ~RH along with dexamethasone to cows with latent ketosis leads to a cure of the condition and prevents mastitis without àffecting the rate of milk production, . - 26 -., ., .
... . .. ~. .. : .

, . - . . . .

Claims (9)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A medicinal composition which comprises both adrenal cortical hormone and thyroid stimulating hormone releasing hormone in a ratio of about 1 (dexamethasone equivalent): 0.05 to 5.

2. The medicinal composition according to claim 1, wherein said adrenal cortical hormone is in the form of a physiologically acceptable ester or salt.

3. The medicinal composition according to claim 1, wherein said thyroid stimulating hormone releasing hormone is in the form of a physiolog-ically acceptable salt.

4. The medicinal composition according to claim 1, 2 or 3 wherein said adrenal cortical hormone and thyroid stimulating hormone releasing hormone are contained in a ratio of about 1 (dexamethasone equivalent): 0.05 to 2.

5. The medicinal composition according to claim 1, 2 or 3 wherein said adrenal cortical hormone is dexamethasone.

6. The medicinal composition according to claim 1, 2 or 3 wherein said adrenal cortical hormone is betamethasone.

7. The medicinal composition according to claim 1, 2 or 3 wherein said thyroid stimulating hormone releasing hormone is L-pyroglutamyl-L-histidyl-L-prolinamide.

8. The medicinal composition according to claim 1, 2 or 3 wherein said adrenal cortical hormone is dexamethasone or betamethasone and wherein said thyroid stimulating hormone releasing hormone is L-pyroglutamyl-L-histidyl-L-prolinamide.

9. The medicinal composition according to claim 1, 2 or 3 which comprises 1 part by weight of dexamethasone or betamethasone as the adrenal cortical hormone and from about 0.05 to 2 parts by weight of L-pyroglutamyl-L-histidyl-L-prolinamide as the thyroid stimulating hormone releasing hormone.